Abstract 168P
Background
China accounts for half of new esophageal cancer (EC) cases in the world. Limited new therapies were developed during the past decades until the advent of immuno-oncology (IO) in 2020. Yet real-world data is scarce for Chinese EC patients prior to IO approval. This nationwide multicenter retrospective study aimed to describe clinical features and treatment patterns of EC in China to capture baseline treatment landscape as the benchmark before IO approval.
Methods
Patient-level data of patients who initiated first therapy for newly diagnosed EC in 2018 were extracted from a large nationwide database. Information within 6 months after initial anti-tumor treatment were obtained and descriptively summarized.
Results
A total of 3493 EC patients from 14 hospitals in China were included in this study, with mean age of 64.1 years at initial diagnosis. The majority of patients were male (75.7%), squamous cell carcinoma (92.8%), with primary lesion at middle (56.4%) esophagus and living in urban area (53.4%). The proportion of stage I, II and III and IV was 14.9%, 31.6%, 39.2%,14.2%, respectively. Out of the 2138 resectable patients, 1986 underwent upfront radical surgery, while 7.1% patients received neoadjuvant therapy, among which chemotherapy was mainstay preoperative therapy (85.5%). Twenty-three percent of resectable patients had adjuvant therapy, with chemotherapy as the mainstream (75.2%) postoperative regimen. For unresectable early and locally advanced patients, the percentage of radical therapy and palliative therapy was 49.9% and 50.1%, respectively, and definitive chemoradiotherapy was the most common treatment (32.0%). For advanced stage patients, chemotherapy accounted for 84.3% of upfront therapy and taxane-based chemotherapy regimen predominated (66.2%).
Conclusions
In this large observational study, most early-stage and locally advanced patients underwent upfront surgery without preoperative treatment, while for advanced patients, chemotherapy was the primary choice. This is the first real-world study of EC to date with largest sample size reflecting Chinese treatment landscape before IO approval, which will help address unmet needs in clinical practice.
Clinical trial identification
EU PAS Register Number: EUPAS48396, release on 29/07/2022.
Editorial acknowledgement
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. MSD China holding.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure
D.F. Shi, Q. Jing, S. Shi, F. Dong: Financial Interests, Personal, Full or part-time Employment: MSD China. All other authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract